Press Releases & Announcements

ACTG ANNOUNCES PUBLICATION OF REPRIEVE SUB-STUDY IN JAMA NETWORK OPEN, PROVIDING INSIGHTS INTO CARDIOVASCULAR DISEASE RISK AMONG PEOPLE LIVING WITH HIV

Jun 30, 2021

ACTG ANNOUNCES CAMOSTAT WILL NOT ADVANCE TO PHASE 3 IN OUTPATIENT TREATMENT STUDY FOR COVID-19

Jun 30, 2021

ACTG LAUNCHES PHASE 1 COMBINATION HIV CURE STUDY

Jun 10, 2021

ACTG ANNOUNCES THE ADDITION OF TWO MONOCLONAL ANTIBODIES TO ACTIV-2 OUTPATIENT TREATMENT STUDY FOR COVID-19

Jun 09, 2021

ACTG HONORS THE 40TH ANNIVERSARY OF HIV/AIDS

Jun 07, 2021

STUDY A5349 PUBLISHED IN NEJM

Jun 07, 2021

CENTRAL MONITORING IN A RANDOMIZED, OPEN-LABEL, CONTROLLED PHASE 3 CLINICAL TRIAL FOR A TREATMENT-SHORTENING REGIMEN FOR PULMONARY TUBERCULOSIS

May 01, 2021

ACTG LEADERSHIP STATEMENT ON DEREK CHAUVIN VERDICT

Apr 22, 2021

ACTG ADDS FIRST POLYCLONAL ANTIBODY TO ACTIV-2 OUTPATIENT TREATMENT STUDY FOR COVID-19

Apr 21, 2021

JOHN. G. GERBER, MD

Mar 04, 2021

ACTG TO PRESENT 24 NEW STUDIES AT CROI 2021

Mar 03, 2021

ACTG ADDS FOUR PROMISING NEW THERAPIES TO ACTIV-2 OUTPATIENT TREATMENT STUDY

Feb 12, 2021